Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0194-0499 + semaglutide
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
NNC0194-0499 + semaglutide is a combination investigational therapy being studied for the treatment of non-alcoholic steatohepatitis (NASH). The combination involves **NNC0194-0499**, an analog of fibroblast growth factor 21 (FGF-21), which is believed to reduce hepatic fat, inflammation, and scarring, and **semaglutide**, a glucagon-like peptide 1 (GLP-1) receptor agonist used as an approved treatment for type 2 diabetes, obesity, and NASH. Semaglutide acts by stimulating insulin secretion, suppressing glucagon, reducing appetite, and slowing gastric emptying. The rationale for the combination is that the two drugs act via complementary mechanisms to address metabolic dysfunction and liver injury associated with NASH[1][3][5][7].
- Other names
- semaglutide + NNC0194-0499semaglutide + FGF21 analog
02
Targets
FGFR1 (Fibroblast growth factor receptor 1)GLP1R (GLP-1R)
Beyond the preview
Go deeper on NNC0194-0499 + semaglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0194-0499 + semaglutide.